Hyam Levitsky

2016

In 2016, Hyam Levitsky earned a total compensation of $2.1M as Executive Vice President, Research and Chief Scientific Officer at Juno Therapeutics, a 85% decrease compared to previous year.

Compensation breakdown

Bonus$28,000
Non-Equity Incentive Plan$131,840
Option Awards$1,534,750
Salary$390,692
Other$43,864
Total$2,129,146

Levitsky received $1.5M in option awards, accounting for 72% of the total pay in 2016.

Levitsky also received $28K in bonus, $131.8K in non-equity incentive plan, $390.7K in salary and $43.9K in other compensation.

Rankings

In 2016, Hyam Levitsky's compensation ranked 4,603rd out of 14,075 executives tracked by ExecPay. In other words, Levitsky earned more than 67.3% of executives.

ClassificationRankingPercentile
All
4,603
out of 14,075
67th
Division
Manufacturing
1,630
out of 5,489
70th
Major group
Chemicals And Allied Products
506
out of 1,895
73rd
Industry group
Drugs
374
out of 1,538
76th
Industry
Biological Products, Except Diagnostic Substances
68
out of 279
76th
Source: SEC filing on April 21, 2017.

Levitsky's colleagues

We found four more compensation records of executives who worked with Hyam Levitsky at Juno Therapeutics in 2016.

2016

Hans Bishop

Juno Therapeutics

Chief Executive Officer

2016

Steven Harr

Juno Therapeutics

Chief Financial Officer

2016

Robert Azelby

Juno Therapeutics

Executive Vice President, Chief Commercial Officer

2016

Bernard Cassidy

Juno Therapeutics

General Counsel

In-depth

You may also like